Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias

Muscle and Nerve

Volumn 43, Issue 2, 2011, Pages 164-167

  Briani, Chiara ^a   Fabrizi, Gian Maria ^b   Ruggero, Susanna ^a   Torre, Chiara Dalla ^a   Ferrarini, Moreno ^b   Campagnolo, Marta ^a   Cavallaro, Tiziana ^b   Ferrari, Sergio ^b   Scarlato, Marina ^c   Taioli, Federica ^b   Adami, Fausto ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Amyloidosis; Neuropathy; POEMS syndrome; Transthyretin; VEGF

Indexed keywords

PREALBUMIN; VASCULOTROPIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MYELOMA; NEUROPATHY; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; POEMS SYNDROME; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78751677431     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21872     Document Type: Article

References (21)

1. Dispenzieri A. POEMS syndrome. Blood Rev 2007;21:285-299.
2. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-596.
3. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-423. (Pubitemid 47512065)
4. Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998;21:1390-1397.
5. Scarlato M, Previtali SC, Carpo M, Pareyson D, Briani C, Del Bo R, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 2005;128:1911-1920.
6. Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003;88:176-185.
7. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-1364.
8. Soubrier M, Dubost JJ, Serre AF, Ristori JM, Sauvezie B, Cathebras P, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum 1997;40:786-787.
9. Gherardi RK, Belec L, Soubrier M, Malapert D, Zuber M, Viard JP, et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood 1996;87:1458-1465. (Pubitemid 26056910)
10. Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000;85:800-805.
11. Nobile-Orazio E, Terenghi F, Giannotta C, Gallia F, Nozza A. Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. Neurology 2009;72:1024-1026.
12. Adami F, Briani C, Binotto G, Altinier S, Tarantini G, Semenzato G. Coexistence of primary AL amyloidosis and POEMS syndrome: efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course. Am J Hematol 2010;85:131-132.
13. Frigerio R, Fabrizi GM, Ferrarini M, Cavallaro T, Brighina L, Santoro P, et al. An unusual transthyretin gene missense mutation (TTR Phe33Val) linked to familial amyloidotic polyneuropathy. Amyloid 2004;11:121-124.
14. Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 2003;17:1961-1966.
15. Kimlinger T, Kline M, Kumar S, Lust J, Witzig T, Rajkumar SV. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. Haematologica 2006;91:1033-1040.
16. Vital C, Vital A, Bouillot-Eimer S, Brechenmacher C, Ferrer X, Lagueny A. Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies. J Peripher Nerv Syst 2004;9:232-241.
17. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520-2530.
18. Vucic S, Chong PS, Cros D. Atypical presentations of primary amyloid neuropathy. Muscle Nerve 2003;28:696-702.
19. Gutierrez A, Turkewitz LJ, Correa H, England JD. Primary systemic amyloidosis presenting with demyelinating features. Neurol Neurophysiol Neurosci 2006:6.
20. Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 2004;63:129-138. (Pubitemid 38943790)
21. Koike H, Kawagashira Y, Iijima M, Yamamoto M, Hattori N, Tanaka F, et al. Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci. J Neurol 2008;255:1526-1533.